CTRI/2018/08/015564招募中3 期
Carboplatin/ paclitaxel versus cisplatin/ 5-fluorouracil as definitive chemoradiotherapy for locoregionally advanced unresectable esophageal and gastroesophageal junction cancer
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients with histologic or cytologic diagnosis of carcinoma (squamous cell carcinoma or adenocarcinoma) of the esophagus or gastroesophageal junction.
- •2.Age >= 18 years
- •3.ECOG performance status (PS) 0-2
- •4.Patient is planned for definitive intent concurrent CRT
- •5.Adequate bone marrow function (hemoglobin > 8 g/L, platelets > 100 x 109/L, absolute neutrophil count (ANC) > 1.5 x 109/L)
- •6.Adequate liver function (ALT/ AST < 2.5 x ULN, serum bilirubin < 2 x ULN)
- •7.Adequate renal function (creatinine clearance >50 ml/ min)
- •8.Women of childbearing potential must be willing to consent to using effective contraception (e.g., hormonal contraceptives, bilateral tubal ligation, barrier with spermicide, intrauterine device) while on treatment and for at least 3 months thereafter. A man who is the partner of a woman of childbearing potential must be willing to consent to using effective contraception (e.g., vasectomy or barrier with spermicide) while on treatment and for 3 months thereafter.
- •9.Willing and able to comply with all study requirements, including treatment, able to be followed up at regular intervals.
- •10.Signed, written informed consent.
排除标准
- •1.Clinical or radiologic evidence of metastatic disease.
- •2.Any significant active infection, including chronic active hepatitis B, active hepatitis C, HIV infection with AIDS or immunodeficiency syndromes. Testing for these is not mandatory unless clinically indicated. Participants with known hepatitis B/ C infection will be allowed to participate, provided evidence of viral suppression has been documented and the patient remains on appropriate anti-viral therapy.
- •3.Serious uncontrolled medical illness (e.g. uncontrolled diabetes mellitus, uncontrolled hypertension, severe infection or untreated psychiatric conditions) that might limit the ability of the patient to comply with the protocol.
- •4.Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, including alcohol dependence or drug abuse.
- •5.History of malignancy other than esophagogastric cancer, except adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix or other malignancies curatively treated with no evidence of disease for > 5 years.
- •6.Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal, infertile, or willing to use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration. Men must have been surgically sterilized or be willing to use a (double if required) barrier method of contraception.
- •7.Use of an investigational agent within the preceding 30 days.
研究者
相似试验
招募中
3 期
To Compare Carboplatin/ Paclitaxel with Cisplatin/ Etoposide in advanced Non Small Cell Lung cancer (NSCLC).CTRI/2020/03/023770Tata Memorial Hospital
进行中（未招募）
不适用
Carboplatin + paclitaxel vs carboplatin + stealth liposomal doxorubicin. A randomised multicentre trial.EUCTR2004-002399-40-DKRigshospitalet530
已完成
3 期
Carboplatin plus nab-Paclitaxel versus docetaxel for elderly squamous non-small cell lung cancer (CAPITAL study)Eldery patients with advanced squamous non-small-cell lung cancerJPRN-UMIN000019843ational Hospital Organization Nagoya Medical Center250
进行中（未招募）
不适用
Paclitaxel poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer (NSCLC) in Women with Estradiol > 30 pg/mlEUCTR2007-004167-22-HUCell Therapeutics, Inc.450
尚未招募
2 期
Comparing two types of chemotherapy in breast cancerCTRI/2017/10/010272Jawaharlal Institute of Post Graduate Medical Education and research